1 / 5

LDL Size and Coronary Risk Predictive value of LDL-particle size Physicians ’ Health Study

LDL Size and Coronary Risk Predictive value of LDL-particle size Physicians ’ Health Study. Relative Risk of M I. * Adjusted RR for total/HDL-cholesterol, plasma apo B level, BMI, diabetes, hypertension, angina and excercice level. At 95 % CI (1.30 - 7.76). 3.18*. 1.

rahim-chapman
Download Presentation

LDL Size and Coronary Risk Predictive value of LDL-particle size Physicians ’ Health Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LDL Size and Coronary RiskPredictive value of LDL-particle sizePhysicians ’ Health Study Relative Risk of M I * Adjusted RR for total/HDL-cholesterol, plasma apo B level, BMI, diabetes, hypertension, angina and excercice level. At 95 % CI (1.30 - 7.76) 3.18* 1 Quintile of LDL diameter Q1 (222 - 250 Å) Q5 (266 - 278 Å)

  2. Les Dyslipidémies • Hyperlipidémies combinées  Chol  TG • Déséquilibre entre  LDL-Chol et  HDL-Chol • Sous-fractions de LDL particulièrement athérogènes • Sous-fractions de HDL peu protectrices • Modifications des apolipoprotéines (adducts, AGE, ALE)  du risque, même pour des concentrations plasmatiques non (ou modérément) augmentées

  3. ACTIONS OF STATINS

  4. Taux de LDL-C vs accidents coronariens dansles principales études sur les statines 4S-P 25 20 15 10 5 0 Prévention secondaire Prévention primaire LIPID-P 4S-S Simvastatine Pravastatine Lovastatine % avec accident coronarien CARE-S CARE-P WOSCOPS-P LIPID-S WOSCOPS-S AFCAPS-S AFCAPS-P 90 110 130 150 170 190 210 LDL-C, mg/dl S = sous statine; P = sous placeboKastelein JJP. Atherosclerosis 1999; 143(suppl 1): S17-S21

  5. * * * Effect of Statin Therapy on hs-CRP Levels at 6 Weeks 6 5 4 3 2 1 0 *p<0.025 vs. Baseline hs-CRP (mg/L) Baseline Prava(40 mg/d) Simva(20 mg/d) Atorva(10 mg/d) Jialal I et al. Circulation 2001;103:1933-1935.

More Related